Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 29;6(4):324.
doi: 10.3390/jof6040324.

Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance

Misti Ellsworth  1 , Luis Ostrosky-Zeichner  2
Affiliations
Review

Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance

Misti Ellsworth et al. J Fungi (Basel). .

Erratum in

Abstract

Increasing incidence of invasive fungal infections combined with a growing population of immunocompromised hosts has created a rising need for antifungal agents. Isavuconazole, a second-generation broad-spectrum triazole with activity against yeasts, dimorphic fungi, and molds, has a favorable safety profile and predictable pharmacokinetics. Patients typically tolerate isavuconazole well with fewer drug-drug interactions. Clinical trials have found it to be noninferior to voriconazole for invasive aspergillosis, an alternative therapy for salvage treatment of mucormycosis, and suitable for stepdown therapy with invasive candidiasis. Cross-resistance with other triazoles is common. More studies are needed to determine the role of isavuconazole in anti-mold prophylaxis in high-risk patients.

Keywords: Aspergillus; Candida; Mucorales; invasive fungal disease; isavuconazole; triazole.

PubMed Disclaimer

Conflict of interest statement

L.O. received speaking, consulting, and/or research funds from Astellas, Pfizer, Cidara, Amplyx, Scynexis, Mayne, F2G, Viracor, and Gilead. M.E. has no reported conflicts.

Figures

Figure 1
Figure 1
Chemical structure of fluconazole, posaconazole, isavuconazole, itraconazole, and voriconazole.
See this image and copyright information in PMC

References

    1. Brown G.D., Denning D.W., Gow N.A., Levitz S.M., Netea M.G., White T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012;4:165rv13. doi: 10.1126/scitranslmed.3004404. - DOI - PubMed
    1. Bongomin F., Gago S., Oladele R.O., Denning D.W. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J. Fungi. 2017;3:57. doi: 10.3390/jof3040057. - DOI - PMC - PubMed
    1. Gallagher J.C., Dodds Ashley E.S., Drew R.H., Perfect J.R. Antifungal pharmacotherapy for invasive mould infections. Expert Opin. Pharmacother. 2003;4:147–164. doi: 10.1517/14656566.4.2.147. - DOI - PubMed
    1. Livermore J., Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin. Drug Metab. Toxicol. 2012;8:759–765. doi: 10.1517/17425255.2012.683859. - DOI - PubMed
    1. Jenks J.D., Salzer H.J., Prattes J., Krause R., Buchheidt D., Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: Design, development, and place in therapy. Drug Des. Dev. Ther. 2018;12:1033–1044. doi: 10.2147/DDDT.S145545. - DOI - PMC - PubMed

LinkOut - more resources